[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536504":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":113,"collaborators":11,"id":115,"slug":11,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":11,"eligibilityCriteria":120,"healthyVolunteers":116,"sex":121,"minAge":122,"maxAge":11,"enrollmentInfo":123,"targetDuration":11,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"CytomX Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CX-2051","EXPERIMENTAL",null,[13],"Drug: CX-2051",{"label":15,"type":10,"description":11,"interventionNames":16},"CX-2051 + bevacizumab",[13,17],"Drug: Bevacizumab",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Investigational drug",[9,15],{"type":20,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Bevacizumab","IV infusion",[15],[28],"Avastin",[30],{"name":31,"affiliation":5,"role":32},"Monika Vainorius, MD","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Karen Deane","CONTACT","650-515-3185","clinicaltrials@cytomx.com",[40,53,63,73,83,93,103],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":11},"Sarah Cannon Research Institute at HealthONE","RECRUITING","Denver","Colorado","80218","United States",{"type":48,"coordinates":49},"Point",[50,51],-104.9847,39.73915,{"lat":51,"lon":50},{"facility":54,"status":42,"city":55,"state":56,"zip":57,"country":46,"cosmosGeoPoint":58,"geoPoint":62,"contacts":11},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":48,"coordinates":59},[60,61],-71.05977,42.35843,{"lat":61,"lon":60},{"facility":64,"status":42,"city":65,"state":66,"zip":67,"country":46,"cosmosGeoPoint":68,"geoPoint":72,"contacts":11},"Montefiore Medical Center","The Bronx","New York","10461",{"type":48,"coordinates":69},[70,71],-73.86641,40.84985,{"lat":71,"lon":70},{"facility":74,"status":42,"city":75,"state":76,"zip":77,"country":46,"cosmosGeoPoint":78,"geoPoint":82,"contacts":11},"Carolina BioOncology Institute, PLLC","Huntersville","North Carolina","28078",{"type":48,"coordinates":79},[80,81],-80.84285,35.41069,{"lat":81,"lon":80},{"facility":84,"status":42,"city":85,"state":86,"zip":87,"country":46,"cosmosGeoPoint":88,"geoPoint":92,"contacts":11},"Sarah Cannon Research Institute, LLC","Nashville","Tennessee","37203",{"type":48,"coordinates":89},[90,91],-86.78444,36.16589,{"lat":91,"lon":90},{"facility":94,"status":42,"city":95,"state":96,"zip":97,"country":46,"cosmosGeoPoint":98,"geoPoint":102,"contacts":11},"START San Antonio LLC","San Antonio","Texas","78229",{"type":48,"coordinates":99},[100,101],-98.49363,29.42412,{"lat":101,"lon":100},{"facility":104,"status":42,"city":105,"state":106,"zip":107,"country":46,"cosmosGeoPoint":108,"geoPoint":112,"contacts":11},"NEXT Virginia","Fairfax","Virginia","22031",{"type":48,"coordinates":109},[110,111],-77.30637,38.84622,{"lat":111,"lon":110},{"type":114,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100536504",false,"NCT06265688","First In Human Study of CX-2051 in Advanced Solid Tumors","An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Measurable disease per RECIST v1.1\n* Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue\n* Additional inclusion criteria may apply\n\nExclusion Criteria:\n\n* Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated\n* Known active central nervous system (CNS) involvement by malignancy\n* Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1\n* Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload\n* Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1\n* Elevated baseline laboratory values\n* Serious concurrent illness\n* Pregnant or breast feeding\n* Additional exclusion criteria may apply","ALL","18 Years",{"count":124,"type":125},160,"ESTIMATED","INTERVENTIONAL",[128],"PHASE1","The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.",[131],"Solid Tumor, Adult","2026-06-23",{"date":134,"type":135},"2026-06-25","ACTUAL",{"date":137,"type":135},"2024-04-02",{"date":139,"type":125},"2029-03-31",{"name":5,"class":6},7]